Biotech New Lows: VIVUS (NASDAQ:VVUS), Dipexium Pharmaceuticals (NASDAQ:DPRX), Tetralogic Pharmaceuticals (NASDAQ:TLOG), Galmed Pharmaceuticals (NASDAQ:GLMD)

VIVUS, Inc. (NASDAQ:VVUS) announced that Shari Belafonte is teaming up with the company to educate American adults about seeking medical treatment for chronic weight management when diet and physical activity alone have not been successful. Ms. Belafonte, an actress, model, photographer, writer, singer and daughter of famed musician and actor Harry Belafonte, knows that the impact of being overweight is more than superficial. VIVUS, Inc. … Continue reading Biotech New Lows: VIVUS (NASDAQ:VVUS), Dipexium Pharmaceuticals (NASDAQ:DPRX), Tetralogic Pharmaceuticals (NASDAQ:TLOG), Galmed Pharmaceuticals (NASDAQ:GLMD)

FB Nasdaq FB Facebook

Biotech Active Runners: Novavax (NASDAQ:NVAX), VIVUS (NASDAQ:VVUS), Rexahn Pharmaceuticals (NYSEMKT:RNN), Ariad Pharmaceuticals (NASDAQ:ARIA)

Novavax, Inc. (NASDAQ:NVAX), announced on Thursday that the Biomedical Advanced Research and Development authority extended the base period of performance of a contract with the pharmaceutical company for its recombinant seasonal and pandemic influenza vaccines. Novavax, Inc. (NASDAQ:NVAX) stock performance was 1.27% in last session and finished the day at $6.38. Traded volume was 13,436,282 million shares in the last session and the average volume … Continue reading Biotech Active Runners: Novavax (NASDAQ:NVAX), VIVUS (NASDAQ:VVUS), Rexahn Pharmaceuticals (NYSEMKT:RNN), Ariad Pharmaceuticals (NASDAQ:ARIA)

Biotech Runners: VIVUS (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

VIVUS Inc. (NASDAQ:VVUS) stock was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating. They now have a $8.00 price target on the stock, down previously from $15.00. VIVUS, Inc. (NASDAQ:VVUS) stock performance was 1.00% in last session and finished the day at $6.09. Traded volume was 5,364,675 million shares in the last session and the average volume … Continue reading Biotech Runners: VIVUS (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

Investors Watch List : Johnson & Johnson (NYSE:JNJ), VIVUS Inc. (NASDAQ:VVUS), SVB Financial Group (NASDAQ:SIVB), AT&T, Inc. (NYSE:T), Modine Manufacturing Company (NYSE:MOD)

Johnson & Johnson (NYSE:JNJ) said on Tuesday that it would pay $1.75 billion in cash for Alios BioPharma, a private biotechnology company that is working on treatments for viral diseases. Johnson & Johnson (NYSE:JNJ) belongs to Healthcare sector. Its net profit margin is 21.20% and weekly performance is -3.03%. On last trading day company shares ended up $103.85. Johnson & Johnson (NYSE:JNJ) distance from 50-day … Continue reading Investors Watch List : Johnson & Johnson (NYSE:JNJ), VIVUS Inc. (NASDAQ:VVUS), SVB Financial Group (NASDAQ:SIVB), AT&T, Inc. (NYSE:T), Modine Manufacturing Company (NYSE:MOD)

News Buzz : Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), VIVUS Inc. (NASDAQ:VVUS), Miller Energy Resources, Inc. (NYSE:MILL), RCS Capital Corporation (NYSE:RCAP), Fred’s, Inc. (NASDAQ:FRED),

Ariad Pharmaceuticals (NASDAQ:ARIA Director Sarah J. Schlesinger bought 5,200 shares of Ariad Pharmaceuticals stock on the open market in a transaction that occurred on Wednesday, September 10th. The shares were purchased at an average cost of $5.73 per share, with a total value of $29,796.00. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) belongs to Healthcare sector. Its weekly performance is -3.27%. On last trading day company shares ended … Continue reading News Buzz : Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), VIVUS Inc. (NASDAQ:VVUS), Miller Energy Resources, Inc. (NYSE:MILL), RCS Capital Corporation (NYSE:RCAP), Fred’s, Inc. (NASDAQ:FRED),

Active Watch List : VIVUS Inc. (NASDAQ:VVUS), Arch Coal Inc. (NYSE:ACI), FXCM Inc. (NYSE:FXCM), U.S. Global Investors (NASDAQ:GROW), Select Income REIT Common (NYSE:SIR)

VIVUS Inc. (NASDAQ:VVUS) The company on Aug. 25 announced the acquisition of a group of patents from Janssen Pharmaceuticals, Inc. covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions. Janssen has agreed to dismiss the lawsuit it brought against VIVUS on August 22, 2014 in the U.S. District Court for the District of Delaware … Continue reading Active Watch List : VIVUS Inc. (NASDAQ:VVUS), Arch Coal Inc. (NYSE:ACI), FXCM Inc. (NYSE:FXCM), U.S. Global Investors (NASDAQ:GROW), Select Income REIT Common (NYSE:SIR)